• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    l4 Abstract A new powder composition which comprises in admixture: lacticacid, at least one disaccharide and at least one compoundwhich binds fat and use of said powder composition for the preparation of a veterinary compound intended for treating and/or preventing a disorder in the auditory canal of mammals.
    公开号:SE1350478A1
    申请号:SE1350478
    申请日:2013-04-16
    公开日:2014-10-17
    发明作者:Claes Thulin
    申请人:Pegion Operations Ltd；
    IPC主号:
    专利说明:

    FIELD OF THE INVENTION Field of the Invention The present invention relates to a new powder composition and to the use of said powder composition for the preparation of a composition or preparation disturbance in the hairy duct in mammals, and more specifically treatment and / or prevention of a non-serious disorder in the ear canal of deer, ie. a disorder that is not so severe that it requires treatment with antibiotics or other forms of medicine, the disorder being selected from the group consisting of otitis externa, pyotraumatic folliculitus and conditions in which the skin is adversely affected by an imbalance in the microflora with an abnormal hag colonization rate of fungi and bacteria.
    Summary of the Invention Otitis externa is known to be one of the most common diseases in the horsel gang of deer, such as dogs and cats, and affects an estimated 15-20 percent of the total dog population. There is a greater susceptibility to external otitis in long-haired dog breeds with hanging anxiety than in dogs or other animals with standing anxiety, with the latter type of Ora being better ventilated.
    Primary causes of external otitis include, but are not limited to, insignificance, keratin formation disorders, foreign bodies, disorders of the ear cartilage and autoimmune patterns. These conditions cause changes in the ear canal that allow abnormal colonization of microorganisms. Susceptibility factors include such 2 conditions as hanging anxiety, stenosis, tumors, Mr. i orat, excessive production of anxiety wax, trauma and high air humidity.
    Other disorders in the hairy duct in mammals are caused by e.g. pyotraumatic folliculitus and conditions under which the skin is adversely affected by an imbalance in the microflora with an abnormally high degree of colonization of fungi and bacteria.
    Existing factors include bacteria (primarily Staphylococcus spp. And Pseudomonas spp.); yeasts (primarily Malassezis spp.); and pathological changes, such as glandular hyperplasia, epithelial folds, neoplasia, edema, mineralization and fibrosis. These conditions are often seen as the cause of anxiety infections.
    Plalassezia pachyermatis is a common commensal organism in the anal sacs, anus, hair follicles and skin of dogs. The lipophilic, oval, budding yeast stone (lipophilic, oval, budding yeast) is a common etiologic agent in otitis extermination canine animals, and can be found in the ear canal in up to 36 percent of normal canines. Factors that promote its growth include abnormal amounts of unrest wax, high humidity and abnormal cell-mediated immunity.
    The above conditions are usually treated with antibiotics or other types of drugs, but given the widespread and sometimes excessive use of antibiotics, the bacteria have developed a resistance to antibiotics, which limits and even counteracts their antibacterial effect. There is a need for new scales to combat the aforementioned disturbances in the horsel passage.
    There are also a number of concern cleaners that are commercially available from veterinarians containing a variety of ingredients, such as alcohols, organic acids, propylene glycol, various peroxides, boric acid and detergents in liquid formulations.
    A problem with liquid compositions / preparations is that, when they are given to the dog's ear canal, which is relatively rank, the dog will shortly afterwards shake its head and much of the liquid is lost. Extensive massage of the Orat / ear canal must therefore be performed when the fluid is inside the ear canal. This treatment is inconvenient for both the dog and the agar.
    The present inventors have therefore focused on a powder composition which is less unpleasant for both the patient and the agar and which has an effect on the growth of microorganisms, in particular fungal growth.
    It is known that yeasts will have a pH of about 3 and Staphylococcus spp. At a pH of about 4.
    The present inventors have thus realized that, by providing a composition which reduces the amount of fat, the degree of moisture and lowers the pH of the ear canal, it is possible to reduce or even eliminate the growth of microorganisms therein.
    The composition according to the invention should also be able to be administered for preventive treatment in order to avoid root problems of the above type.
    More specifically, the inventors are of the opinion that by lowering the pH value has the horsel passage to about 4, Staphylococcus will do, which meant that Malassezis will no longer have access to nicotinic acid, which is produced by Staphylococcus, and by binding moisture, Malassezis will no longer to be able to proliferate, and by binding fat, in which Malassezis dr "dissolved", Malassezis is prevented from colonizing the cell wall. The present invention relates to a novel powder composition comprising lactic acid, at least one disaccharide and at least one compound which binds fat, the amount of lactic acid being such that the pH value of the composition is not lower than 3.
    The present invention also relates to the use of the powder composition identified above for the preparation of a preparation for veterinary use intended for the treatment and / or prevention of a disorder of the mammary gland, the disorder being selected from the group consisting of otitis externa, pyotraumatic folliculitis and which the skin is adversely affected by an imbalance in the microflora with an abnormally high degree of colonization of fungi and bacteria.
    An example of a compound which reduces the pH value is lactic acid, and the amount of lactic acid in the composition according to the invention is about 0.01-2, preferably 0.05-1.5, and in particular 0.1-1% by weight of the total composition. , and has a particle size of about 101,000, preferably 300-900, and especially 500-800 microns.
    Examples of compounds which reduce the degree of moisture and which at the same time lower the pH value in the ear canal are mono-, di- and oligosaccharides. One such example is lactose which binds moisture and which is converted by the microorganisms into lactic acid, thus forming an acidic environment in the ear canal, whereby a synergistic effect is obtained together with the lactic acid, which forms part of the composition according to the invention. The composition of the invention comprises lactose in an amount of about 15-60, preferably 10-55, and especially 15-50% by weight of the total composition, and has a particle size of about 1200, preferably 7.5-150, and especially 15-50% by weight. 100 um.
    Examples of compounds that bind fats are alkyl polyglucoside, derivatives of glucamine and aluminosilicate. Particularly preferred is kaolin, and the composition of the invention comprises kaolin in an amount of about 20-80, preferably 30-75, and especially 40-70% by weight of the total composition, and has a particle size of about 0.1-30, preferably 0.8-20, and especially 1.2-10 pm.
    The composition of the present invention may also contain one or more additional compounds selected from the group consisting of chlorhexidine, silica and L-fucose.
    If chlorhexidines are in the composition, the amount thereof is about 0.01-2, preferably 0.05-1.5, and especially 0.1-1% by weight of the total composition, and has a particle size of about 3-300, preferably -250, and especially 100-200 pm.
    If silica contains in the composition the amount thereof of about 0.1-10, preferably 0.35-7, and especially 0.5-3% by weight of the total composition, and has a particle size of about 50-400, preferably 100- 350, and especially 150-250 pm.
    If L-fucoses are present in the composition, the amount thereof is about 0.5-10, preferably 1-5, and especially 1.5-3% by weight of the total composition, and has a particle size of about 200-800, preferably 300-700. , and especially 400-600 pm.
    Since the powder composition according to the invention is to be administered into the resin passage, which preferably takes place with a dispensing device, the composition should form a light, airy powder.
    In order to demonstrate the applicability of the powder composition according to the invention, two studies are challenged with respect to responses that dogs experience when a change occurs in the normal balance of the microflora in the ear canal. In a first study, Example 1, the composition according to the invention without content of any fungicidal or bacterial agents was compared with a common powder composition comprising boric acid on the market. 17 dogs that met certain criteria were included in and completed this study, and two veterinarians confirmed the presence of external otitis by ocular examination, ie. that the dogs showed clinical signs, such as reddening of the skin, itching and shaking of the head.
    The duration of the study was three weeks and the dose administered for the inventive composition was 0.15 grams per Ora.
    The study was performed as follows: i) The veterinarian examined the dog and showed the dog owner how the powder composition should be administered. ii) The dog sitter administered one dose per Ora every six days.
    After day six, the dog eater administered one dose per week for two weeks.
    Three weeks after the veterinarian had examined the dog, the dog was re-examined by the veterinarian. It should be noted that the results represent a general evaluation of the clinical signs.
    The results of this study are given in Example 1 below. Example 1 Dog Rate Rate Result 1 z2t Good 2 y3q Good 3 y3q Good 7 4 z2t Good 7 z2t Good 8 z2t Less good 9 z2t Less good z2t Good 11 z2t Good 12 z2t Good 13 z2t Good 14 z2t Less good z2t Good 16 y3q Less good 17 y3q Good 18 y3q Good 19 y3q Good z2t Is an existing powder composition comprising boric acid. The composition of the invention contains 30.0% by weight of lactose, 68.9% by weight of kaolin, 1.0% by weight of silica and 0.1% by weight of lactic acid.
    In a further study, Example 2 below, 12 dwarf schnauzers, all of which showed clinical signs as itchy and had black waxy substance in the horsel gel, were treated with the composition of the invention with added chlorhexidine.
    The length of the study was 29 days. During the first four days, the dogs received a dose of 0.15 grams of the powder composition according to the invention per grout and day. From day 6 to day 26, the 8 dogs received the same dose once a week. The horsel passage was not massaged and any excess powder in the horsel passage was not dried off. For the most part, the dogs shook their heads and the excess disappeared.
    The powder composition of the invention in Example 2 was composed of 30.0% by weight of lactose, 68.75% by weight of kaolin, 1.0% by weight of silica, 0.1% by weight of lactic acid and 0.15% by weight of chlorhexidine.
    Example 2 Day 0 Day Day 12 Day 19 Day 26 Dog 1 Itched his Anxiety, black waxy substance in the ear canal Did not itch his anxiety. The black substance was almost gone No cuddling, no black substance left, the horsel passage can be considered as normal Normal hair passage Normal hair passage Dog 2 Itched his worries, black waxy substance in the horse passage did not scratch his worries. The black substance was almost gone No cuddling, no black substance left, the ear canal can be considered son normal Normal ear canal Normal ear canal Dog 3 Itched its arons, black waxy substance in the ear canal did not itch its Oron. The black substance was almost gone No cuddling, no black substance left, the horsel passage can be considered normal Normal heirsel passage Normal horsel passage Dog 4 Itched his worries, black wax did not scratch his worries.
    The black No cuddling, no black Normal horselgang Normal horselgang 9 substance in horselgAngen the substance was almost gone substance left, horselgAngen can be considered normal Dog Itched his 6ron, black waxy substance in heirselgAngen did not itch his 6ron. The black substance was almost gone No cuddling, no black substance left, horselgAngen can be considered normal Normal horselgang Normal horselgAng Dog 6 Itched his 6ron, black waxy substance in horselgAngen did not itch his 6ron. The black substance was almost gone No cuddling, no black substance left, horselgAngen can be considered normal Normal horselgAng Normal horselgAng Dog 7 Itched his 6ron, black waxy substance in horselgAngen did not itch his 6ron. The black substance was almost gone No cuddling, no black substance left, the horselgang can be considered normal Normal horselgang Normal horselgang Dog 8 Itched his worries, black waxy substance in the horselgAngen did not itch his 6ron. The black substance was almost gone No cuddling, no black substance left, the hearing loss can be considered normal Normal hearing loss Normal hearing loss Dog 9 Itched his 6rons, black waxy substance in the hearing loss Not itched his 6rons. The black substance was almost gone No cuddling, no black substance left, the hearing loss can be considered Normal hearing loss Normal hearing loss 10 as normal Dog Itched his worries, black waxy substance in the hearing aisle Did not scratch his worries. The black substance was almost gone No tickling, no black substance left, the hair follicle can be considered normal Normal ear canal Normal ear canal Dog 11 Itched his worries, black waxy substance in the ear canal Did not itch sinaron.
    The black substance was almost gone No cuddling, no black substance left, the horsel passage can be considered normal Normal horsel passage Normal hare passage Dog 12 Itched his worries, black waxy substance in the harsel passage did not scratch his worries. The black substance was almost gone No cuddling, no black substance left, the hazel can be considered normal Normal hazel Normal hazel In a further study, only a few dogs were treated with the same symptoms as the dogs in Example 1 with the same dosage regimen as in the said Example and with the according to the invention the powder composition containing 30.0% by weight of lactose, 68.99% by weight of kaolin, 1.0% by weight of silica, and 0.01% by weight of lactic acid. The results for the treated dogs were similar to the results obtained in Example 1.
    In the powder composition according to the invention, the upper limit for the amount of lactic acid is about 2.0% by weight, since tests have shown that this will give a pH value of about 3, which is the lower limit which can be tolerated without causing irritation of the horse passage. In addition, all of the powder compositions of the invention studied above contain silica, according to the inventors, that silica can be excluded from the compositions, since the main function of silica is that the river forma has the powder composition and the amount is at most 10% by weight of the total composition.
    The amount of the other ingredients of the composition according to the invention, in particular concerning kaolin, lactose and silica, need not be carefully limited as long as they are within the limits stated above.
    The starting dose given to small dogs is about 0.15 grams of the composition according to the invention per hour and day for the first 5 to 6 days, and for larger dogs this dose is about 0.30 grams and for the largest dog this dose is about 0 , gram. Due to the fact that most dogs will shake their heads when they are given the composition according to the invention, part of the composition will be lost and will thus not reach the ear canal.
    It should be noted that the inventor has realized that the composition according to the invention can be administered for maintenance treatment to avoid anxiety problems of the above types. The dosing regimen for maintenance therapy is about 0.0 to 0.45 grams per dose depending on the size of the dog per Ora and is given once a week.
    权利要求:
    Claims (9)
    [1] 1. lO l
    [2] 2. Claims l. A powder composition which comprises in admixture: lacticacid, at least one disaccharide and at least one compoundwhich binds fat, wherein the amount of lactic acid issuch that the pH of the composition is not less than
    [3] 3.The powder composition according to claim l, wherein thesaid composition comprises 0.0l-2, preferably 0.05-l.5,and particularly 0.l-l percent by weight of lactic acid,5-60, preferably l0-55, and particularly l5-50 percent byweight of said at least one disaccharide, and 20-80,preferably 30-75, and particularly 40-70 percent byweight of said at least one compound which binds fat. The powder composition according to claim l or 2, whereinsaid at least one disaccharide is lactose, and whereinsaid at least one compound which binds fat is kaolin. The powder composition according to claim 3, wherein theparticle size of said lactic acid is l-200, preferably7.5-l50, and particularly l5-l00um, the particle size ofsaid lactose is l-200, preferably 7.5-l50, andparticularly l5-l00um, and the particle size of saidkaolin is 0.l-30, preferably 0.8-20, and particularlyl.2-l0um. The powder composition according to any of the precedingclaims, wherein the composition further comprises atleast one additional compound selected from the groupconsisting of chlorhexidine, silica, and L-Fucose. The powder composition according to claim 5, wherein theamount of chlorhexidine is 0.0l-2, preferably 0.05-l.5,and particularly 0.l-l percent by weight and having aparticle size of about 3-300, preferably 25-250, andparticularly l00-200um, wherein the amount of silica is0.l-l0, preferably 0.35-7, and particularly 0.5-3 percentby weight and having a particle size of about 50-400, 10. 13 preferably 100-350, and particularly l50-250um, andwherein the amount of L-Fucose is 0.5-10, preferably l-5,and particularly 1.5-3 percent by weight and having aparticle size of about 200-800, preferably 300-700, andparticularly 400-600um. A use of the powder composition according to any ofclaims l-6 for preparation of a veterinary compoundintended for treating and/or preventing a disorder in theauditory canal of mammals, the disorder being selectedfrom the group consisting of otitis externa, pyotraumaticfolliculitus and conditions in which the skin is affectedin a negative way by an unbalance in the microflora withan abnormal high degree of colonization of fungus andbacteria. The use the powder composition according to claim 7 forpreparation of a veterinary compound, which powercomposition, for acute treatment, is administrated in anamount of 0.15-0.45 grams per dose per day and ear duringa period of 5 to 6 days. The use the powder composition according to claim 7 forpreparation of a veterinary compound, which powercomposition, for maintenance treatment, is administratedin an amount of 0.05 to 0.45 grams per dose and ear, saiddose being given once a week. The use the powder composition according to any of claims7-9 for preparation of a veterinary compound, wherein the mammals are dogs and cats.
    类似技术:
    公开号 | 公开日 | 专利标题
    JP6908568B2|2021-07-28|Substances and methods for treating conditions associated with pathogenic biofilms
    JP2011522808A|2011-08-04|Synergistic preservative mixture
    JP2014522403A|2014-09-04|Method of treating mammalian nipple and related compositions
    JP2012507545A|2012-03-29|Emulsion-based topical preparation storage system
    CZ302297B6|2011-02-09|Mildew-proof mixture containing Pythium oligandrum fungal organism
    Banovic et al.2013|In vitro comparison of the effectiveness of polihexanide and chlorhexidine against canine isolates of Staphylococcus pseudintermedius, Pseudomonas aeruginosa and Malassezia pachydermatis
    SE1350478A1|2014-10-17|Powder composition and use of said powder composition for the treatment of a mammalian hearing disorder
    CN109223736A|2019-01-18|Composition, the drug and preparation method thereof for preventing and treating animal foot rot
    Pan et al.2006|Efficacy of an injectable formulation of eprinomectin against Psoroptes cuniculi, the ear mange mite in rabbits
    JP5990344B2|2016-09-14|Synergistic preservative blend
    RU2642617C1|2018-01-25|Complex preparation for treatment of acute and chronic otites of parasitary, bacterial and fungical origin in dogs, cats, fur-bearing animals and rabbits
    AU2009203892B2|2014-10-30|Treatment for dermatological conditions
    KR20170086019A|2017-07-25|Compositions useful for the prevention and/or treatment of infections and inflammations
    RU2430722C1|2011-10-10|Agent for prevention and treatment of mastitis in cows
    JP2020525452A5|2021-03-25|
    ES2489298B1|2015-06-11|USE OF EREMOFILAN SESQUITERPENOS AS GARRAPATICIDAS
    RU2668535C2|2018-10-01|Method of prophylaxis of mastitis in high-producing cows
    DE102013105666A1|2014-12-04|Probiotic strains, compositions containing probiotic strains and pharmaceutical agents
    RU2599489C1|2016-10-10|Agent for treating cow udder
    BR112021002950A2|2021-05-11|compositions acting synergistically to reduce microbes comprising aromatic alcohol, glyceryl ether and bispyridinium alkane and use of these compositions
    CN106421560A|2017-02-22|Disinfectant for pets
    US20100190854A1|2010-07-29|Composition and method to treat mastitis
    US8968803B1|2015-03-03|Powdered teat dip
    CZ30803U1|2017-07-03|A preparation for the treatment of bovine mammary glands with plant extracts
    Wallis2013|Case study: reduction in bulk tank somatic cell count on a commercial dairy associated with use of a Streptococcus uberis bacterin
    同族专利:
    公开号 | 公开日
    JP2016517855A|2016-06-20|
    SE537168C2|2015-02-24|
    JP6401243B2|2018-10-10|
    WO2014171873A1|2014-10-23|
    ES2658085T3|2018-03-08|
    HK1214155A1|2016-07-22|
    EP2986279A4|2016-10-26|
    EP2986279A1|2016-02-24|
    CN105228594A|2016-01-06|
    KR20160005335A|2016-01-14|
    EP2986279B1|2017-12-20|
    CA2908931A1|2014-10-23|
    PL2986279T3|2018-04-30|
    US20160081931A1|2016-03-24|
    US10130583B2|2018-11-20|
    CA2908931C|2021-03-23|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    GB865672A|1957-06-27|1961-04-19|Boots Pure Drug Co Ltd|Antiseptic therapeutic compositions comprising 2:4-dichlorobenzyl alcohol|
    JPS60163807A|1984-02-06|1985-08-26|Kao Corp|Pack|
    JPH0242010A|1988-08-01|1990-02-13|Sansho Seiyaku Co Ltd|Make-up cosmetic|
    JP3600779B2|2000-05-12|2004-12-15|ミンクルプロダクツ株式会社|Powdery cosmetics|
    WO2004035071A1|2002-10-17|2004-04-29|Nakar, Herzl|Herbal medicine containing cyclodextrins for the treatment of ear disorders|
    JP2004315468A|2003-04-18|2004-11-11|Hakuto Co Ltd|Skin care preparation for external use|
    US20050009790A1|2003-07-08|2005-01-13|Laszlo Sichtnik|Ear and wound treatment|
    EP1858506A2|2005-03-10|2007-11-28|3M Innovative Properties Company|Methods of treating ear infections|
    CN101278917A|2008-02-28|2008-10-08|王世锋|Method for preparing povidone iodine vaginal tablet|
    JP5346533B2|2008-09-29|2013-11-20|株式会社マンダム|Powdered solid antiperspirant deodorant|WO2016182455A1|2015-05-12|2016-11-17|Ouch-Ie Powder Company Limited|New treatment methods utilising lactose compositions|
    CN109602761B|2018-12-04|2020-12-22|华南理工大学|Application of kaolinite as antibiotic resistance gene inhibitor|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    SE1350478A|SE537168C2|2013-04-16|2013-04-16|Powder composition and use of said powder composition for treating a hearing disorder in mammals|SE1350478A| SE537168C2|2013-04-16|2013-04-16|Powder composition and use of said powder composition for treating a hearing disorder in mammals|
    JP2016508923A| JP6401243B2|2013-04-16|2014-04-14|Powder composition and use thereof for treating disorders in the ear canal of mammals|
    PL14785638T| PL2986279T3|2013-04-16|2014-04-14|Powder composition for treating a disorder in the auditory canal of mammals and use thereof|
    CA2908931A| CA2908931C|2013-04-16|2014-04-14|Powder composition for treating a disorder in the auditory canal of mammals and use thereof|
    ES14785638.9T| ES2658085T3|2013-04-16|2014-04-14|Powder composition to treat a disorder in the mammalian ear canal and its use|
    EP14785638.9A| EP2986279B1|2013-04-16|2014-04-14|Powder composition for treating a disorder in the auditory canal of mammals and use thereof|
    KR1020157029203A| KR20160005335A|2013-04-16|2014-04-14|Powder composition for treating a disorder in the auditory canal of mammals and use thereof|
    CN201480021006.5A| CN105228594A|2013-04-16|2014-04-14|Be used for the treatment of powder composition and the application thereof of mammal auditory meatus disease|
    US14/784,636| US10130583B2|2013-04-16|2014-04-14|Powder composition for treating a disorder in the auditory canal of mammals and use thereof|
    PCT/SE2014/000049| WO2014171873A1|2013-04-16|2014-04-14|Powder composition for treating a disorder in the auditory canal of mammals and use thereof|
    HK16102200.4A| HK1214155A1|2013-04-16|2016-02-25|Powder composition for treating a disorder in the auditory canal of mammals and use thereof|
    [返回顶部]